Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline • Types of Krabbe disease PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing • Market size and forecast PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE ANALYSIS PART 09: MARKET SEGMENTATION BY THERAPY • Segmentation by therapy • Comparison by therapy • Global Krabbe disease treatment market by anticonvulsants • Global Krabbe disease treatment market by muscle relaxants • Global Krabbe disease treatment market by HSCT • Global Krabbe disease treatment market by others • Market opportunity by therapy PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Krabbe disease treatment market in Americas • Krabbe disease treatment market in EMEA • Krabbe disease treatment market in APAC • Key leading countries • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Emergence of pharmacological chaperone therapy • Gene technology in therapy PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • GlaxoSmithKline • Johnson & Johnson • Novartis PART 17: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Types of Krabbe disease Exhibit 02: Parent market Exhibit 03: Global rare diseases treatment market: Segmentation Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition: Inclusions and exclusions checklist Exhibit 07: Market size Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global Krabbe disease treatment market 2017-2022 ($ millions) Exhibit 10: Global Krabbe disease treatment market: Year over year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Pipeline landscape by development phase Exhibit 19: Key clinical trials for global Krabbe disease treatment market Exhibit 20: Global Krabbe disease treatment market by therapy 2017-2022 (% share) Exhibit 21: Comparison by therapy Exhibit 22: Global Krabbe disease treatment market by anticonvulsants 2017-2022 ($ millions) Exhibit 23: Global Krabbe disease treatment market by anticonvulsants: Year over year growth 2018-2022 (%) Exhibit 24: Global Krabbe disease treatment market by muscle relaxants 2017-2022 ($ millions) Exhibit 25: Global Krabbe disease treatment market by muscle relaxants: Year over year growth 2018-2022 (%) Exhibit 26: Global Krabbe disease treatment market by HSCT 2017-2022 ($ millions) Exhibit 27: Global Krabbe disease treatment market by HSCT: Year over year growth 2018-2022 (%) Exhibit 28: Global Krabbe disease treatment market by others 2017-2022 ($ millions) Exhibit 29: Global Krabbe disease treatment market by others: Year over year growth 2018-2022 (%) Exhibit 30: Market opportunity by therapy Exhibit 31: Customer landscape Exhibit 32: Global Krabbe disease treatment market by region 2017-2022 (% share) Exhibit 33: Regional comparison Exhibit 34: Krabbe disease treatment market in Americas 2017-2022 ($ millions) Exhibit 35: Krabbe disease treatment market in Americas: Year over year growth 2018-2022 (%) Exhibit 36: Krabbe disease treatment market in EMEA 2017-2022 ($ millions) Exhibit 37: Krabbe disease treatment market in EMEA: Year over year growth 2018-2022 (%) Exhibit 38: Krabbe disease treatment market in APAC 2017-2022 ($ millions) Exhibit 39: Krabbe disease treatment market in APAC: Year over year growth 2018-2022 (%) Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Some long-term complications in HSCT patients Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: GlaxoSmithKline: Overview Exhibit 49: GlaxoSmithKline: Business segments Exhibit 50: GlaxoSmithKline: Organizational developments Exhibit 51: GlaxoSmithKline: Geographic focus Exhibit 52: Johnson & Johnson: Segment focus Exhibit 53: GlaxoSmithKline: Key offerings Exhibit 54: GlaxoSmithKline: Key customers Exhibit 55: Johnson & Johnson: Overview Exhibit 56: Johnson & Johnson: Business segments Exhibit 57: Johnson & Johnson: Organizational developments Exhibit 58: Johnson & Johnson: Geographic focus Exhibit 59: Johnson & Johnson: Segment focus Exhibit 60: Johnson & Johnson: Key offerings Exhibit 61: Johnson & Johnson: Key customers Exhibit 62: Novartis: Overview Exhibit 63: Novartis: Business segments Exhibit 64: Novartis: Organizational developments Exhibit 65: Novartis: Geographic focus Exhibit 66: Novartis: Segment focus Exhibit 67: Novartis: Key offerings Exhibit 68: Novartis: Key customers

GlaxoSmithKline, Johnson & Johnson, and Novartis.